HONG KONG – South Korean med-tech venture Recens Medical Inc. has secured ₩7 billion (US$6 million) in series B funding. Lb Investment Inc., Kb Securities Co. Ltd., Bnk Securities Co. Ltd., Hyundai Venture Investment Corp. and Lighthouse Combined Investment Co. Ltd. participated in the investment.
Rarecyte Inc., a Seattle-based company making products for tissue and cell analysis, reported picking up $22 million in a series F financing round led by Healthquest Capital. Also participating in the round were existing investors 5AM Ventures and Ron Seubert, Rarecyte’s founder and chief technology officer. The company plans to use the funds to expand global sales of its instruments and consumables platform in research clinical markets.
PARIS – Biolog-id SAS, specialists in traceability and management of delicate health care products (red blood cells, plasma, platelets and chemotherapy substances), has just raised $33 million from fund managers Xerys Gestion. “Thanks to this new funding, we will be able to roll out our smart traceability solutions worldwide. These are used for managing labile blood products and plasma fractionation,” Jean-Claude Mongrenier, founder and CEO of the Boulogne-Billancourt, France-based company, told BioWorld MedTech.
DUBLIN – Truffle Capital closed off its fifth Biomedtech fund with a €250 million (US$279 million) raise, which it will deploy in about a dozen companies located mainly in France. The fund took a little longer to close than originally planned but it is significantly larger than it had originally intended. “Our initial objective was €200 million,” Truffle Capital CEO and co-founder Philippe Pouletty told BioWorld MedTech.
Medford, Mass.-based startup Sofregen Medical Inc. has picked up $8 million in a series B round led by Anzu Partners LLC. The money is earmarked for continued development of Sofregen’s silk protein-based technology and for commercialization of its U.S. FDA-cleared Silk Voice for people with vocal cord problems.
RSS
